Novogen (NASDAQ:KZIA) Shares Up 3.7% – What’s Next?

Novogen Limited (NASDAQ:KZIA) shot up 3.7% during trading on Monday . The stock traded as high as $12.23 and last traded at $11.40. 183,127 shares traded hands during mid-day trading, a decline of 7% from the average session volume of 197,319 shares. The stock had previously closed at $10.99.

Analysts Set New Price Targets

Several brokerages have commented on KZIA. Laidlaw began coverage on Novogen in a research note on Wednesday, April 15th. They issued a “buy” rating and a $25.00 target price for the company. Wall Street Zen downgraded Novogen from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a research note on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Novogen Stock Up 0.7%

The firm has a fifty day simple moving average of $11.41 and a two-hundred day simple moving average of $9.20.

Novogen (NASDAQ:KZIA) last released its quarterly earnings results on Saturday, February 14th. The company reported ($1.34) earnings per share for the quarter. The business had revenue of $4.89 million during the quarter. As a group, equities research analysts forecast that Novogen Limited will post -0.01 earnings per share for the current year.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.